1. An imaging apparatus for providing anatomical, hemodynamical, molecular, and functional information on a subject in an integrated form, the imaging apparatus comprising:
a first scanner for obtaining said anatomical and hemodynamical information;
a second scanner for obtaining said molecular and functional information;
an RF shield for switching between an open status and a close status, the RF shield being configured to shelter a predetermined space including said first scanner from external RF fields in said close status;
a transferring railway running along a path from said first scanner via said RF shield to said second scanner; and
a bed movable along said transferring railway system and for supporting said subject.
2. The imaging apparatus of claim 1, wherein said RF shield comprises a shutter which also equipped the same at a junction with said transferring railway, said shutter being configured to open only if said bed passes.
3. The imaging apparatus of claim 1, wherein said transferring railway is sufficiently rigid to maintain coordinates for said subject between said first and second scanners.
4. The imaging apparatus of claim 3, wherein said first and second scanners each comprises a laser-guided calibration means for maintaining coordinates for said subject.
5. The imaging apparatus of claim 1, further comprising an imaging processor for constructing a fused image by processing anatomical information obtained by said first scanner, and molecular and functional information obtained by said second scanner.
6. The imaging apparatus of claim 1, wherein said first scanner is a Low-Field MRI scanner, and said second scanner is a PETCT scanner.
7. The imaging apparatus of claim 1, wherein said first scanner is a micro-MRI scanner, and said second scanner is a micro-PET scanner.
8. A computer-readable recording medium, storing a program comprising instructions for a computer to operate the apparatus of claim 1.
9. A computer-readable recording medium for storing a program comprising instructions for a computer to perform mathematical or computer techniques necessary to fuse anatomical information, hemodynamical information and molecular and functional information which are obtained by the apparatus of claim 1.
10. A method of providing anatomical, hemodynamical, molecular and functional information on a subject, the method comprising the steps of:
transferring said subject to a space where said anatomical and hemodynamical information are obtained;
sheltering said space from external RF fields where said anatomical and hemodynamical information is obtained;
obtaining said anatomical information;
transferring said subject to a space where said molecular and functional information are obtained; and
obtaining said molecular and functional information.
11. A computer-readable recording medium, storing a program comprising instructions for a computer to perform the method of claim 10.
12. An imaging apparatus for providing anatomical, hemodynamical, molecular and functional information on a subject, the imaging apparatus comprising:
a first scanner for obtaining said anatomical information as well as hemodynamical information on said subject in an integrated form;
a second scanner for obtaining said molecular and functional information;
an RF+ magnetic shield for sheltering a first predetermined space including said first scanner from external RF fields and for preventing magnetic fields of said first scanner from leaking outside;
a magnetic shield for sheltering a second predetermined space including said second scanner from said magnetic fields out of said first scanner;
a transferring railway system running along a line from said first scanner via said \u201cRF+ magnetic\u201d shield and said \u201cmagnetic\u201d shield to said second scanner; and
a bed movable along said transferring railway and for supporting said subject.
13. The imaging apparatus of claim 12, wherein said \u201cRF+ magnetic\u201d shield and said \u201cmagnetic\u201d shield each comprises a shutter which also equipped the same at a junction with said transferring railway.
14. The imaging apparatus of claim 13, wherein said shutter of said RF+ magnetic shield and said shutter of said magnetic shield are controlled in a completely synchronized manner so that both said shutters are not open at the same time to assure a complete magnetic shield for said second scanner at any given time.
15. The imaging apparatus of claim 12, wherein said transferring railway is sufficiently rigid and accurate to maintain coordinates for said subject between said first and second scanners.
16. The imaging apparatus of claim 15, wherein said first and second scanners each comprises a laser-guided calibration means for maintaining coordinates for said subject.
17. The imaging apparatus of claim 12, further comprising an imaging processor for constructing a fused image by processing anatomical and hemodynamical information obtained by said first scanner, and molecular and functional information obtained by said second scanner.
18. The imaging apparatus of claim 12, wherein said first scanner is a UHF-MRI scanner, and said second scanner is an HRRT-PET scanner.
19. The imaging apparatus of claim 12, further comprising a means for rotating said transferring railway by any of degrees, said means for rotating being placed between said RF+ magnetic shield and said magnetic shield.
20. A computer-readable recording medium, storing a program comprising instructions for a computer to operate the apparatus of claim 12.
21. A computer-readable recording medium, storing a program comprising instructions for a computer to perform mathematical and computer techniques necessary to fuse anatomical and hemodynamical information, and molecular and functional information which are obtained by the apparatus of claim 12.
22. A method of providing anatomical and hemodynamical and molecular and functional information on a subject, the method comprising the steps of:
transferring said subject to a first space where said anatomical and hemodynamical information is obtained;
sheltering from external RF fields said first space and preventing leakage of magnetic fields to the outside from said first space;
obtaining said anatomical and hemodynamical information;
transferring said subject to a second space where said molecular and functional information are obtained;
sheltering the said second space from external magnetic fields ; and
obtaining said molecular and functional information.
23. The method of claim 22, wherein the step of transferring said subject to a space where said molecular and functional information are obtained further comprises a step of blocking magnetic fields leaked from said space where said anatomical and hemodynamical information are obtained.
24. The method of claim 23, wherein the step of transferring said subject to a space where said molecular and functional information is obtained comprises a step of rotating said subject by arbitrary degrees before said subject arrives at the shutter of said second space where said molecular and functional information is obtained.
25. A computer-readable recording medium, storing a program comprising instructions for a computer to perform the method of claim 22.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof:
wherein
R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;
R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl;
or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring;
R4 is C1-C3 alkyl, C2-C3 alkenyl, \u2014N(\u2014R5)\u2014R6, or optionally substituted heteroarylmethylamino; and
R5 and R6 are independently selected from hydrogen or C1-C3 alkyl;
or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.
2. A compound as claimed in claim 1 wherein R1 is an optionally substituted 5- or 6-membered heteroaryl ring.
3. A compound as claimed in claim 1 wherein R1 is an optionally substituted 5-membered heteroaryl ring.
4. A compound as claimed in claim 1 wherein R1 is optionally substituted thienyl.
5. A compound as claimed in claim 4 wherein R1 is thienyl optionally substituted by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.
6. A compound as claimed in claim 1 wherein R1 is thien-2-yl.
7. A compound as claimed in claim 1 wherein R2 is hydrogen, or a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof.
8. A compound as claimed in claim 7 wherein R2 is hydrogen.
9. A compound as claimed in claim 7 wherein R2 is an optionally substituted 5- or 6-membered monocyclic heteroaryl group linked via a C1-C6 alkylene chain.
10. A compound as claimed in claim 7 wherein R2 is a 5- or 6-membered monocyclic heteroaryl group linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.
11. A compound as claimed in claim 1 wherein R3 is hydrogen, or a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof.
12. A compound as claimed in claim 11 wherein R3 is an optionally substituted 5- or 6-membered monocyclic heteroaryl group linked via a C1-C6 alkylene chain.
13. A compound as claimed in claim 11 wherein R3 is a 5- or 6-membered monocyclic heteroaryl group linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.
14. A compound as claimed in claim 1 wherein R4 is amino.
15. A compound as claimed in claim 1 wherein R4 is mono C1-C3 alkylamino.
16. A compound as claimed in claim 15 wherein R4 is methylamino.
17. A compound as claimed in claim 15 wherein R4 is ethylamino.
18. A compound as claimed in claim 1 wherein R4 is C1-C3 alkyl.
19. A compound as claimed in claim 18 wherein R4 is ethyl.
20. A compound of formula (II) or a pharmaceutically acceptable salt, hydrate or solvate thereof:
wherein
R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;
R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl;
or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; and
R4 is hydrogen or C1-C3 alkyl.
21. A compound as claimed in claim 20 wherein R1 is thien-2-yl.
22. A compound as claimed in claim 20 wherein R2 is hydrogen and R3 is pyrid-3-ylmethyl.
23. A compound as claimed in claim 20 wherein R4 is hydrogen or methyl.
24. A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
25. (canceled)
26. A method of treating a disorder mediated by the adenosine A2B receptor comprising the administration to a subject suffering such a disorder an effective amount of a compound as claimed in claim 1.
27. The method as claimed in claim 26 wherein the disorder mediated by the adenosine A2B receptor is nociception, asthma, COPD, an inflammatory disorder, diabetes, diabetic retinopathy, or cancer.
28. A method as claimed in claim 27 for nociception, asthma, COPD, inflammatory disorders, diabetes, diabetic retinopathy, or cancer, by selective antagonism of A2B activity over A2A activity.